Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

Marketplace

Hematology systems, middleware software, 9/13

Sysmex America recently introduced its Sysmex XP-300, an update for smaller labs in the U.S. and recently introduced to the Latin America and Caribbean market, as well as its Sysmex DI-60 integrated slide processing system, which provides seamless integration of automated slide making/staining and digital cell image classification. The Sysmex XP-300 automated hematology analyzer is part of the company’s three-part differential analyzer portfolio and combines the reliability and heritage of the KX-21N with updated, user-friendly software. The XP-300 has a

End-stage renal disease test, 9/13

EKF Diagnostics offers a novel test to accurately identify diabetic patients at high risk of progression to end-stage renal disease (ESRD) up to 10 years before currently available tests can. EKF’s sTNFr1 test is an ELISA assay that has the potential to significantly improve diabetic patient management and outcomes. The test accurately detects circulating levels of soluble tumor necrosis factor receptor 1 (sTNFr1) in patient samples. Research has demonstrated that high circulating levels of sTNFr1 are strongly associated with progression

Rapid strip-based hemoglobin test, 9/13

EKF Diagnostics offers its Stat-Site M Hgb strip-based test for quick and easy hemoglobin analysis for rapid anemia determination. Stat-Site M Hgb is a portable handheld analyzer. The pocket-sized device delivers accurate hemoglobin analysis results within 30 seconds from 15 µL of fingerstick whole blood. This hemoglobin photometer is maintenance-free and includes intuitive, step-by-step on-screen instructions to minimize operator training. Its durability, portability, and user-friendliness make the device especially suited to blood screening programs in developing world markets. It also

β-hydroxybutyrate strip test, 9/13

EKF Diagnostics’ Stat-Site M β-HB is a strip-based test for β-hydroxybutyrate that provides a quick and easy assessment of diabetic ketoacidosis (DKA), delivering results in less than 80 seconds. The presence and degree of ketosis can be assessed rapidly at the point of care by accurately measuring blood levels of β-HB, which accounts for 78 percent of the three ketone bodies, from 10 µL of serum or plasma. This results in useful information to provide quality care when monitoring DKA

DNA enrichment kits, 9/13

EKF Diagnostics offers its EKF Molecular Diagnostics’ PointMan DNA enrichment kits. The three kits are for enriching mutations in BRAF, KRAS, and EGFR T790M genes associated with skin melanoma and colorectal and lung cancers. PointMan kits provide highly specific and ultrasensitive enrichment of mutant genes in a background of wild-type (normal) genes. PointMan real-time PCR technology provides reliable and extremely sensitive detection for cancer mutations. The technology is highly efficient at amplifying the target sequence of interest, while suppressing amplification

Laboratory analyzer workflow interface, 9/13

The IVD Industry Connectivity Consortium (IICC) has developed a laboratory analyzer workflow (LAW) interface, which is a global interface based on a common set of clinical laboratory communications that unambiguously define communication protocols. In 2012, four diagnostic and three IT companies successfully validated 129 LAW tests. Since then, IICC has refined these interfaces and is asking more manufacturers to adopt the standard in an effort to simplify connectivity in the clinical laboratory and within the health care enterprise. Benefits of

Reference solutions for bath salt metabolites, 9/13

Cerilliant offers seven new certified spiking solutions of bath salt metabolites. The new products are 1.0 mg/mL (as free base) in methanol for the primary urinary metabolites of bath salt cathinones, mephedrone, buphedrone, pentedrone, flephedrone, N-ethylcathinone, and 4-methylethcathinone. For GC/MS and LC/MS methods that quantify concentrations of synthetic cathinone metabolites, the company also offers the corresponding deuterium-labeled internal standard. Cerilliant offers certified Snap-N-Spike solutions for use in clinical toxicology applications, medication monitoring, forensic analysis, employee drug screening, and urine drug

Reference solutions for thyroid hormones, 9/13

Cerilliant offers certified Snap-N-Spike solutions of thyroid hormones T4, T3, and reverse T3 at concentrations of 100 µg/mL in 0.1 N ammonia in methanol for each solution standard. These certified spiking solutions are for use as critical starting materials in the preparation of calibrators, controls, or linearity standards for analytical testing including LC-MS/MS analysis of free and total thyroid hormone levels. Comprehensive certificates of analysis (COAs) come with every Cerilliant certified reference standard and include all analytical data from full

Sanger sequencing system and HLA typing kits, 9/13

Life Technologies in February received FDA 510(k) clearance for its 3500 Dx genetic analyzers and SeCore HLA typing kits. The company’s 7500 Fast Dx real-time PCR system was cleared for diagnostic use with the CDC’s H1N1 assay in 2008. The Applied Biosystems 3500 Dx/3500xL Dx CS2 genetic analyzers, Invitrogen SeCore HLA sequencing kits, and uType Dx HLA sequence analysis software constitute the first FDA 510(k)-cleared sequence-based system for HLA typing in the United States. HLA typing on the 3500 Dx

General-purpose reagents, 9/13:80 (AACC)

NanoString Technologies’ nCounter Elements are digital molecular bar-coding chemistry assay components that allow users to assemble their own assays with oligonucleotide probes that target their genes of interest. The components enable highly multiplexed, direct profiling of individual molecules in a single reaction without amplification and are effective for a range of applications requiring efficient, high-precision quantitation of tens to hundreds of target molecules across a sample set. This chemistry generates high-quality results from challenging sample types, such as FFPE tissue

MARKETPLACE

TRENDING